Associate Professor, Radiation Oncology, Vanderbilt University School of Medicine
Radiation Oncology
Dr. Eric T. Shinohara, MD
|
|
Give Review
Dr. Eric T. Shinohara practices Radiation Oncology. He went to medical school at Vanderbilt University School of Medicine. Dr. Eric T. Shinohara is also published. He has 39 publications published. The lastest publication: "Distance to Radiation Facility and Treatment Choice in Early-Stage Breast Cancer.' Eric Shinohara is registered with Medicare.
Publications
- Role of radiation in the treatment of non-metastatic osseous Ewing sarcoma.
- Evidence of high mortality in long term survivors of childhood medulloblastoma.
- The Refusal of Palliative Radiation in Metastatic Non-Small Cell Lung Cancer and Its Prognostic Implications.
- Long-term outcomes and late effects for childhood and young adulthood intracranial germinomas.
- Postoperative radiation boost does not improve local recurrence rates in extremity soft tissue sarcomas.
- Subsequent malignancies and their effect on survival in patients with retinoblastoma.
- Late causes of death in children treated for CNS malignancies.
- Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma.
- Outcome for Children with Metastatic Solid Tumors over the Last Four Decades.
- The use of gene therapy in Cancer research and treatment.
- The controversial abscopal effect.
- Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate Cancer.
- Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment.
- The role of radiation therapy in malignant thymoma: a Surveillance, Epidemiology, and End Results database analysis.
- Brachytherapy in the treatment of cholangiocarcinoma.
- Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation.
- ATM polymorphism IVS62+60G>A is not associated with disease aggressiveness in prostate Cancer.
- The use of tyrosine kinase inhibitors in modifying the response of tumor microvasculature to radiotherapy.
- STI571 (Gleevec) improves tumor growth delay and survival in irradiated mouse models of glioblastoma.
- Clusterin as a therapeutic target for radiation sensitization in a lung Cancer model.
- Murine double minute 2 as a therapeutic target for radiation sensitization of lung Cancer.
- DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs.
- Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
- Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.
- Endostatin polymorphism 4349G/A(D104N) is not associated with aggressiveness of disease in prostate [corrected] Cancer.
- Radiosensitization of lung Cancer by nutlin, an inhibitor of murine double minute 2.
- Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas.
- Sirolimus as a potential radiosensitizer in squamous cell Cancer of the head and neck.
- Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma.
- Esophageal Cancer in a young woman with bulimia nervosa: a case report.
- The role of mTOR inhibition in augmenting radiation induced autophagy.
- Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests.
- Active integration: new strategies for transgenesis.
- PDGFR-beta expression in small cell lung Cancer patients.
- Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation.
- E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate Cancer in Caucasian patients.
- SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation.
- Distance to Radiation Facility and Treatment Choice in Early-Stage Breast Cancer.
Schools
Vanderbilt University
Conditions Treated
- Pituitary Gland Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Education
-
University of Pennsylvania Health System -
Vanderbilt University School of Medicine
Hospital
-
Vanderbilt Hospital and Clinics -
Williamson Medical Center
Drug Facts
| NPI NUMBER | 1780740571 | |
| NPPES Provider LastName | SHINOHARA | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 372325671 | |
| NPPES Provider State | TN | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 22.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1780740571 |
| Last Name Of The Provider | SHINOHARA |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
|
Dr. James R. Gray Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kenneth M. Lloyd, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony J. Cmelak, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. My T. Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas A. Hunter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arnold W. Malcolm, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Andrew S. Kennedy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Albert Attia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Austin N. Kirschner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert W. Mutter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey M. Friedman, MD |